Stephen L Shiao, Kenneth H Gouin, Nathan Ing, Alice Ho, Reva Basho, Aagam Shah, Richard H Mebane, David Zitser, Andrew Martinez, Natalie-Ya Mevises, Bassem Ben-Cheikh, Regina Henson, Monica Mita, Philomena McAndrew, Scott Karlan, Armando Giuliano, Alice Chung, Farin Amersi, Catherine Dang, Heather Richardson, Wonwoo Shon, Farnaz Dadmanesh, Michele Burnison, Amin Mirhadi, Zachary S Zumsteg, Rachel Choi, Madison Davis, Joseph Lee, Dustin Rollins, Cynthia Martin, Negin H Khameneh, Heather McArthur, Simon R V Knott
Strategies are needed to better identify patients that will benefit from immunotherapy alone or who may require additional therapies like chemotherapy or radiotherapy to overcome resistance. Here we employ single-cell transcriptomics and spatial proteomics to profile triple negative breast cancer biopsies taken at baseline, after one cycle of pembrolizumab, and after a second cycle of pembrolizumab given with radiotherapy. Non-responders lack immune infiltrate before and after therapy and exhibit minimal therapy-induced immune changes...
January 8, 2024: Cancer Cell